Gilead's CAR-T Therapy Yescarta Slowly Getting Off The Ground
Executive Summary
Slow and steady approach to launch should position Yescarta well in the long run, Gilead maintains – the CAR-T therapy brought in $7m in its first month. But Gilead is still suffering from the decline in hepatitis C.
You may also be interested in...
Pharma Q3 Results Preview: Biogen, Gilead, Celgene
Ozanimod re-filing is a big near-term catalyst for Celgene. Biogen investors will be looking for more information about the development and regulatory strategy for BAN2401 in Alzheimer's. And Gilead investors want reassurance that the company will return to growth soon.
Pharma Q2 Results Preview: Celgene, Amgen, Allergan And AbbVie
With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.
Pharma Q2 Results Preview: Celgene, Amgen, Allergan And AbbVie
With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.